argenx posts strong Q2 2026 with expanded VYVGART label
Jul 23, 2026, 1:05 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong Q2 growth and large absolute sales validate the VYVGART franchise; US label expansion broadens TAM; multiple near-term readouts (ALKIVIA 3Q26, ADVANCE-NEXT 1H27) present catalysts that could drive multiple expansion. Cash runway of $5.2B reduces liquidity risk and supports accelerated R&D, potentially lowering near-term funding concerns. Risks include execution of pipeline programs and potential competition; nonetheless, catalysts point to upside in the 6–12 month window.
AI summary
What happened, with direct paths to the underlying reporting
Argenx reported Q2 2026 product net sales of $1.5B, up 60% YoY and 17% QoQ. The US label expansion for VYVGART/VYVGART Hytrulo to cover all gMG serotypes broadens patient access, while topline readouts for ALKIVIA (3Q26) and ADVANCE-NEXT (1H27) bolster near-term visibility. The company also reiterated Vision 2030 goals and a $5.2B cash position, supporting accelerated R&D and commercialization plans.
Q2 2026 product net sales $1.5B; up 60% YoY, 17% QoQ.
Expanded VYVGART/VYVGART Hytrulo label to all gMG serotypes in US.
ALKIVIA MM myositis readout expected 3Q26; ADVANCE-NEXT ITP topline 1H27.
VYVGART SC autoinjector expected to launch in 2027.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
argenx announced positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis (IMNM+DM), meeting the primary endpoint with a 15.4-point mean TIS improvement…
argenx is acquiring Forte Biosciences for $77 per share in cash, valuing Forte at about $2.2 billion. Forte's FB102 anti-CD122 antibody has Phase 1b signals in vitiligo and celiac…
Argenx updated its Phase 3 myositis plan, separating IMNM and DM analyses and dropping PM. HC Wainwright remains bullish on Vyvgart, citing IMNM's potential to exceed $1B in sales…
The FDA has approved a significant label expansion for Argenx's VYVGART, allowing its use in all serotype adult patients with generalized myasthenia gravis. This comes after posit…
